Experience of Health Care Reform An overview of SB 459 GOO OOD S - - PowerPoint PPT Presentation

▶
experience of health care reform an overview of sb 459
SMART_READER_LITE
LIVE PREVIEW

Experience of Health Care Reform An overview of SB 459 GOO OOD S - - PowerPoint PPT Presentation

Feb 22, 2024 382 likes •814 views

Experience of Health Care Reform An overview of SB 459 GOO OOD S SAMARITAN D DRUG O OVERDOS OSE E ACT Laurie e Squartsoff NV V Department o of f Health a and d Human S Servi vice ces Roadmap o of P Prese esentation n Origin

slide-1
SLIDE 1

Experience of Health Care Reform An overview of SB 459

GOO OOD S SAMARITAN D DRUG O OVERDOS OSE E ACT

Laurie e Squartsoff NV V Department o

  • f

f Health a and d Human S Servi vice ces

slide-2
SLIDE 2

Roadmap o

  • f P

Prese esentation n

Origin and Development of Successful Reform Implementation Outcomes State Contacts / Additional Resources

2

slide-3
SLIDE 3

3

slide-4
SLIDE 4

Origin a and D Development o t of S Succe ccessful l Reform m NE NEVAD ADA D A DATA

  • 2nd h

high ghest t for hydrocodone prescriptions (ARCOS)

  • 2nd h

high ghest t for oxycodone prescriptions (ARCOS)

  • 4th h

high ghest t for methadone prescriptions (ARCOS)

  • 7th h

high ghest t for codeine prescriptions (ARCOS)

  • 4th h

high ghest t drug overdose mortality rate (Vital Statistics)

  • Over 19% of Nevada High Schools students report that they

have taken prescription drugs without a doctor’s prescription (YRBS)

4

slide-5
SLIDE 5

Origin a and D Development o t of S Succe ccessful l Reform m The goal al of the NGA Prescription Drug Abuse Prevention program is is, with improved coordination of statewide resources, to

  • reduce

ce t the e inci cidence o

  • f i

inappropriate e controlled s d substan ance u use b by y Nevad adan ans. .

5

slide-6
SLIDE 6

Origin a and D Development o t of S Succe ccessful l Reform m

  • Data Defined Goals
  • Reduce overall prescriptions of hydrocodone and oxycodone (ARCOS data) as

well as expansion of MAT providers (DEA) and prescribers (SAPTA) and assurance to access to comprehensive, fully integrated treatment (Medicaid data to access)

  • Reduce the number of overdose deaths (Vital Statistics, Coroner data)
  • Reduce number of high school students that have used a prescription drug

without a prescription (YRBS)

6

slide-7
SLIDE 7

Origin a and D Development o t of S Succe ccessful l Reform m

Timeline Date Milestone July 2014 Announced as Rx Drug Policy Academy Co-Lead September 2014 First meeting with National Governors Association (NGA) staff and other states Ongoing Stakeholder meetings, core team subcommittee meetings April 2015 Legislative hearings May 5, 2015 Stakeholder meetings, SB459 Signed into Law June 2015 Reconvening of all states at NGA meeting in Vermont September 2015 Report turned over to Chief of Staff at Governor’s office

7

slide-8
SLIDE 8

Mandatory Use PDMP PDMP Prescriber Education ID Requirement Support for Doctor Shopping Naloxone Use Law Good Samaritan Support for Law Substance Use Services Physical Exam Requirement Pharmacy Lock-In Requirement Program

Origin a and D Development o t of S Succe ccessful l Reform m

Source linked at end of presentation. Teal slices were TFAH/ASTHO strategies already in place in Nevada and orange slices were added by SB 459.

8

slide-9
SLIDE 9

Key c components of

  • f SB 45

459 9

  • Mandatory Use of PMP
  • Prescriber Education Requirement
  • Good Samaritan Law
  • Support for Naloxone use
slide-10
SLIDE 10

Roadmap o

  • f P

Presentation n

Origin and Development of Successful Reform

Implementation

Outcomes State Contacts / Additional Resources

10

slide-11
SLIDE 11

Implementa ntation n

  • Data collection
  • Community Education
  • Provider Education
  • Law Enforcement
  • Assessment and Treatment

11

slide-12
SLIDE 12

Implementation n

  • The Nevada DHHS, Substance Abuse and Prevention Agency (SAPTA) and

the Multidisciplinary Prevention Advisory Committee (MPAC) and the State Epidemiologic Workgroup (SEW) were selected to manage implementation.

  • MPAC is a partner advisory group with the SEW, both of which advise
  • SAPTA. The SEW collects and analyzes the data and the MPAC 's role is to

create recommendations on strategies and funding in relation to the information the SEW presents. The MPAC also receives Coalition updates.

  • The MPAC meetings provide regular updates on statewide efforts. SAPTA

tracks progress and shares information with Governor’s office.

12

slide-13
SLIDE 13

Roadmap o

  • f P

Presentation n

Origin and Development of Successful Reform Implementation

Outcomes

State Contacts / Additional Resources

13

slide-14
SLIDE 14

Key c components of

  • f SB 45

459 9

  • Mandatory Use of PMP
  • Prescriber Education Requirement
  • Good Samaritan Law
  • Support for Naloxone use
slide-15
SLIDE 15

Outcomes

Mandatory access and use by practitioners of Prescription Monitoring Program(PMP)

  • Practitioners are required to obtain a PMP report before initiating

some prescriptions for a controlled substance

slide-16
SLIDE 16

Outcomes PRESCRIPTION MONITORING PROGRAM

  • Prescription is for a controlled substance (Schedule II,III, or IV)
  • Patient is a new patient for the practitioner; or
  • The prescription is for more than 7 days and is part of a new course of

treatment for the patient

slide-17
SLIDE 17

Outcomes PRESCRIPTION MONITORING PROGRAM

  • Practitioners are obligated to actually review the PMP reports
  • NRS639.23507(1) does not apply to inpatient chart orders; it does

apply to prescriptions written for out-patients by practitioners working in a hospital emergency department

slide-18
SLIDE 18

Outcomes PRESCRIPTION MONITORING PROGRAM

  • Periodic training for practitioners concerning the misuse and abuse of

controlled substances

  • The language in sections 15.1 through 15.9 is permissive, not

mandatory:

slide-19
SLIDE 19

Outcomes PRESCRIPTION MONITORING PROGRAM

  • The language in sections 15.1 through 15.9 is permissive, not

mandatory: Each Board “may, by regulation, require…who is registered to dispense controlled substances pursuant to NRS 453.231 to complete at least 1 hour of training relating specifically to the misuse and abuse of controlled substances during each period of

  • licensure. Any such holder of a license may use such training to satisfy

1 hour of any continuing education requirement established by the Board.”

slide-20
SLIDE 20

Outcomes

ADDITIONAL PROVISIONS IN SB459

  • Ability for practitioners to “Red Flag” Doctor Shoppers – Section 13
  • Next Day reporting to the PMP Database Section -13(2)
slide-21
SLIDE 21

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Authority to Prescribe and Dispense to Non-Patients
slide-22
SLIDE 22

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Section 7 of SB459 applies to a health care professional otherwise

authorized to prescribe an opioid antagonist may directly or by standing order, prescribe and dispense and opioid antagonist to a person other than the patient.

slide-23
SLIDE 23

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Section 7 describes other persons as “a family member, friend or
  • ther person in a position to assist such a person at risk of

experiencing an opioid-related drug overdose.”

slide-24
SLIDE 24

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Significant departure from traditional pharmacy law. Outside the

scope of SB459, prescriptions must be written for the patient in a prescriber-patient relationship. See NRS 639.235(2) and (4). Prescribers cannot generally write prescriptions for persons who are merely related to or associated with the patient.

slide-25
SLIDE 25

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Per the statute, such prescriptions are to be regarded as “being issued

for a legitimate medical purpose in the usual course of professional practice.” Section 7(1)

  • Prescribers who write such a prescription in good faith and with care

are immune from civil or criminal prosecution directly associated with writing the prescription. Section 7(2)

slide-26
SLIDE 26

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Section 7(3), not withstanding any other provision of law, any person

may possess and administer an opioid antagonist to another person who he or she reasonable believe is experiencing an opioid-related drug overdose.

slide-27
SLIDE 27

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Any person is undefined, but the statute specifically states that law

enforcement personnel, EMTs, advanced emergency medical technicians or paramedics are included, as being able to possess and administer an opioid antagonist

slide-28
SLIDE 28

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Persons who act in good faith and with reasonable care in

administering an opioid antagonist- although they would have no legal authority to administer other medications-are immune from criminal prosecution, civil liability and sanction from professional licensing boards. Section 7(4)

slide-29
SLIDE 29

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Section 7(5) does not create a duty to prescribe or dispense an opioid
  • antagonist. A prescriber who declines to prescribe the medication for

any reason is immune from criminal, civil and administrative proceedings

slide-30
SLIDE 30

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Section 8 Authority of unlicensed persons to store, possess and

administer opioid antagonists

slide-31
SLIDE 31

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Section 8 allows non-registered persons to store and dispense opioid

antagonists pursuant to a standing order from a properly authorized

  • prescriber. The caveat is that ‘those activities [must be] undertaken

without charge or compensations.” Where the person has a standing

  • rder from a prescriber, the person can possess and dispense without

charge without a license from the Board of Pharmacy pursuant to NRS Chapter 639.

slide-32
SLIDE 32

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Authority of pharmacists to dispense opioid antagonists in

accordance with standardized procedures or protocols developed and approved by the State Board of Pharmacy

  • Recent workshop held on October 15, 2015
  • Another workshop scheduled for December 2015
  • Pending regulations will be forwarded to LCB before adoption
slide-33
SLIDE 33

Outcomes

GOOD SAMARITAN OVERDOSE ACT

  • Section 12 addresses protections for persons who seek medical

assistance for another person who is experiencing a drug or alcohol

  • verdose
slide-34
SLIDE 34

Outcomes

GOOD SAMARITAN OVERDOSE ACT

Section 12(1) says that if a person seeks aid in good faith on behalf of himself/herself, or for another, that person “may not be arrested, charged, prosecuted or convicted, or have his or her property subjected to forfeiture” or other penalty.

slide-35
SLIDE 35

Outcomes

GOOD SAMARITAN OVERDOSE ACT

Even in cases where immunities in subsection 12(1) do not apply, the Court, before sentencing, “shall consider in mitigation any evidence or information that the defendant, in good faith, sough medical assistance for a person in connection with the events that led to the violation.” Section 12(2).

slide-36
SLIDE 36

Outcomes

ISSUES STILL AT HAND

  • Section 10: DHHS MAY MONITOR/WATCH CHANGE

TRENDS IN RISK FACTORS AND PUBLISH ANNUAL REPORT

slide-37
SLIDE 37

Outcomes

IMPORTANT TO ASSURE THAT “PAIN” PATIENTS RECEIVE APPROPRIATE TREATMENT WITHOUT BARRIERS

slide-38
SLIDE 38

Roadmap o

  • f P

Presentation n

Origin and Development of Successful Reform Implementation Outcomes State Contacts / More Information

38

slide-39
SLIDE 39

State C Contacts s / / More I Informati tion n

State Contacts Larry Pinson, Pharm.D., Nevada State Board of Pharmacy; lpinson@pharmacy.nv.gov; 775-850-1440 Tracey Green MD, Chief Medical Officer: tgreen@health.nv.gov, 775-684-3215 Dena Schmidt, Deputy Director, DHHS: dena.schmidt@dhhs.nv.gov, 775-684-4015 Laurie Squartsoff, R.Ph, DPBH: lasquartsoff@health.nv.gov, 725-500-2913 More Information Nevada Legislature: http://www.leg.state.nv.us/ SB459: https://www.leg.state.nv.us/App/NELIS/REL/78th2015/Bill/2161/Text SAPTA: http://mh.nv.gov/Meetings/SAPTA_Program_Page/ Trust for America’s Health Report: http://healthyamericans.org/reports/drugabuse2013/ Data Resources: http://dpbh.nv.gov/Programs/OPHIE/Public_Health_Informatics_and_Epidemiology_-_Home/ YRBS data for NV: https://dhs.unr.edu/chs/research/yrbs

39

slide-40
SLIDE 40

Experience of Health Care Reform An overview of SB 459

40

slide-41
SLIDE 41

Experience of Health Care Reform An overview of SB 459

Thank y k you

  • u!

41